🇺🇸 FDA

Intelligence · Clinical Pipeline

Neurology & CNS R&D Pipeline

Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Programs
676

Quick answer

Neurology & CNS: NovaPharmaNews indexes 676 neurology & cns clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Alzheimer's, Parkinson's, epilepsy, MS, and CNS pipeline assets tracked by phase and sponsor.

Top sponsors

Page 6 of 15

  1. Armodafinil

    Teva Pharma GmbH

    Bipolar I Depression

    phase 2 small molecule completed

    1 trial

  2. Atomoxetin STADA 40 mg Hartkapseln, GELATIN

    Pari Pharma GmbH

    Healthy subjects with no neurological or psychiatric disorders

    phase 2 small molecule active

    1 trial

  3. Azeliragon

    vTv Therapeutics

    Alzheimer Disease

    phase 2 small molecule terminated

    1 trial

  4. B-CIT and SPECT imaging

    United Therapeutics Europe Ltd

    Parkinson Disease

    phase 2 small molecule completed

    1 trial

  5. BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  6. BHV-7000, BHV-7000, Placebo for BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 2 small molecule active

    1 trial

  7. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  8. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  9. BMB-101

    BRIGHT MINDS BIOSCIENCES INC.

    Absence Epilepsy

    phase 2 small molecule active

    1 trial

  10. Bepranemab, Placebo matching and without active substance, Neuraceq 300 MBq/mL solution for injection, (18F) GTP1

    Lacuna Pharma Pty Ltd

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  11. Berubicin hydrochloride

    Rani Therapeutics Holdings

    central nervous system (CNS) lymphomas

    phase 2 small molecule active

    1 trial

  12. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  13. Bupropion

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia and Disorders With Psychotic Features

    phase 2 small molecule completed

    1 trial

  14. CC-97489, CC-97489, CC-97489 1mg , CC-97489 3mg

    Celgene Europe Limited

    Multiple Sclerosis Spasticity

    phase 2 small molecule active

    1 trial

  15. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  16. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  17. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  18. CET/PT

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 other completed

    1 trial

  19. CNSA-001

    PTC THERAPEUTICS, INC.

    Gastroparesis

    phase 2 small molecule completed

    1 trial

  20. CT1812

    COGNITION THERAPEUTICS INC

    Early Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  21. CT1812

    COGNITION THERAPEUTICS INC

    Mild to Moderate Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  22. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    3 trials

  23. CT1812

    COGNITION THERAPEUTICS INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  24. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Parkinson's Disease

    phase 2 small molecule terminated

    1 trial

  25. CX-8998

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  26. Cannabidiol Capsules, Füllstoffmischung DAC in hardshell gelatine capsules, size 1, is used as placebo. Füllstoffmischung DAC consists of mannitol 99.5 % and silloidal silicon dioxide (Aerosil®) 0.5 %.

    The George Institute

    Remitted early phase schizophrenia

    phase 2 small molecule active

    1 trial

  27. Clonazepam

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  28. DAAOI-P

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Parkinson's Disease With Dementia

    phase 2 small molecule completed

    1 trial

  29. DMTs + taurine

    The First People's Hospital of Lianyungang

    Multiple Sclerosis (MS) Relapsing Remitting

    phase 2 small molecule active

    1 trial

  30. Dexmedetomidine

    COGNITION THERAPEUTICS INC

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

  31. Diazepam Buccal Film

    Aquestive Therapeutics

    Epilepsy

    phase 2 small molecule completed

    2 trials

  32. Diazepam Buccal Film 12.5 mg

    Aquestive Therapeutics

    Epilepsy

    phase 2 small molecule completed

    1 trial

  33. Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  34. EBVALLO

    Pierre Fabre Medicament

    EBV+ primary imunodeficiency lymphoproliferative disease (LPD), EBV+ post-transplant LPD where standard first line therapy (rituximab or chemotherapy) is inappropriate, including CD20-negative disease, EBV+ sarcomas, including leiomyosarcoma, or smooth muscle tumors, EBV+ associated post-transplant LPD involving the central nervous system (EBV+ CNS PTLD)

    phase 2 small molecule active

    1 trial

  35. Evaluation of the safety and efficacy of Continuous Dopaminergic Stimulation by intracerebroventricular administration of anaerobically conserved dopamine in Parkinson's disease at the motor fluctuation stage: Single-center pilot study

    Lacuna Pharma Pty Ltd

    Parkinson's disease

    phase 2 other active

    1 trial

  36. Everolimus

    BRIGHT MINDS BIOSCIENCES INC.

    Epilepsy

    phase 2 small molecule active

    1 trial

  37. Exercise Programme

    United Therapeutics Europe Ltd

    Parkinson's Disease

    phase 2 other completed

    1 trial

  38. FLORBETAPIR, Placebo to match LY, Flortaucipir, Donanemab

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  39. Florquinitau F-18, Sodium Chloride, PRX005

    Bristol-Myers Squibb Australia Pty Ltd

    Early Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  40. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  41. Fluoxetine

    The First People's Hospital of Lianyungang

    Depression

    phase 2 small molecule active

    1 trial

  42. Fycompa 2 mg film-coated tablets, Fycompa 2 mg film-coated tablets, Fycompa 0.5 mg/ml oral suspension, Fycompa 2 mg film-coated tablets

    Eisai Co.,

    Childhood Epilepsy

    phase 2 small molecule active

    1 trial

  43. GSK4527226

    GlaxoSmithKline

    Alzheimer's Disease

    phase 2 small molecule active

    1 trial

  44. GWP42003-P

    Jazz Pharmaceuticals Ireland Limited

    Schizophrenia

    phase 2 small molecule terminated

    1 trial

  45. GWP42003-P 5 mg/kg/day Dose

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    1 trial

  46. GWP42006

    Jazz Pharmaceuticals Ireland Limited

    Epilepsy

    phase 2 small molecule completed

    2 trials

  47. GXV813, GXV813, Placebo 0 mg Hard gelatin capsule

    Novartis Pharmaceuticals

    Schizophrenia

    phase 2 small molecule active

    1 trial

  48. Glatiramer Acetate, N-Acetylcysteine

    Teva Pharma GmbH

    Relapse Remitting Multiple Sclerosis

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many neurology & cns pipeline programs are tracked?

676 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.